BRIDGE PHARMA, INC.
LAKEWOOD RANCH, FLORIDA

BRIDGE PHARMA, Inc. is a privately held research and development firm specialized in the pharmaceutical sector with a keen focus on projects exhibiting blockbuster potential. The company caters to unmet medical needs within expanding global markets by developing innovative therapies that offer significant enhancements over existing treatments. BRIDGE PHARMA boasts several high-potential research endeavors and has an experienced project team recognized for developing numerous successfully marketed drugs. Its current human projects encompass the development of novel medications targeting atopic dermatitis, asthma, pruritus, allergic conjunctivitis, and dry eye disease (xerophthalmia). In the veterinary domain, projects include treatments for canine atopic dermatitis, canine xerophthalmia, and repartitioning agents for livestock growth promotion. Based in Sarasota, Florida, BRIDGE PHARMA collaborates with GLSynthesis, Inc. in Worcester, Massachusetts for chemistry research, and partners with various Contract Research Organizations (CROs) and specialists across the US, Canada, Europe, and New Zealand for biological laboratory research. The company develops its drugs through preclinical phases before seeking out-licensing partners, having achieved licensing deals across diverse segments such as local anesthetics, urinary urge incontinence, ocular projects, and livestock growth promotion. BRIDGE PHARMA is a Florida domestic profit corporation (DOMP), incorporated on June 11, 1996. The main office is located at 14107 Nighthawk Terrace, LAKWOOD RANCH, FL, 34202. As per the latest records, its status reflects an amendment noted on June 29, 2008, with its last annual report submitted on February 8, 2024, covering the year 2024. Its filing number is P96000049736, and it holds a Federal Employer Identification Number of 650671012. The company's leadership comprises Gunnar Aberg as President Designate (PD) and Laurie Aberg in a senior role.